Mielke D H, Gallant D M, Kessler C
Am J Psychiatry. 1977 Dec;134(12):1371-5. doi: 10.1176/ajp.134.12.1371.
Sulpiride is a new and chemically different neuroleptic. In a study of 16 severely ill schizophrenic patients, this compound displayed definite evidence of antipsychotic activity while producing few adverse reactions. The relative absence of extrapyramidal side effects may indicate that sulpride has a low potential for producing tardive dyskinesia. Two patients who did not develop significant increases in prolactin levels did show a definite therapeutic response to sulpiride. Thus it appears that central dopaminergic blockade in the hypothalamic area is not a prerequisite for antipsychotic activity.
舒必利是一种新型的、化学结构不同的抗精神病药物。在一项针对16名重症精神分裂症患者的研究中,这种化合物显示出明确的抗精神病活性证据,同时产生的不良反应很少。锥体外系副作用相对较少,这可能表明舒必利导致迟发性运动障碍的可能性较低。两名催乳素水平没有显著升高的患者确实对舒必利表现出明确的治疗反应。因此,下丘脑区域的中枢多巴胺能阻断似乎不是抗精神病活性的先决条件。